Regulatory News:

Genomic Vision (the “Company” - FR0011799907 – GV) (Paris:GV), a biotechnology company that develops tools and services dedicated to the analysis and control of changes in the genome, today announces the successful publication of the patent on “Physical Characterization of Telomeres” (PCT).

The patent was granted by the U.S. Patent and Trademark Office (USPTO) and The World Intellectual Property Organization (WIPO) in June 2022. With this patent, Genomic Vision has been actively building its inventive portfolio focused on bringing the new dimension and utilization of the company’s molecular combing technology into the field of age-related diseases and cancer onsets.

What are Telomeres?

Telomeres are the protective caps at the ends of all the chromosomes in human body. Each time a cell divides, the telomeres become slightly shorter. Eventually, a time comes when the telomere become so short that the cells cannot divide and thus, die. Based on this phenomenon, identification of telomere shortening, or loss has opened a vast domain of biological and chronological age-related disease which can lead to breakthrough for medicine in addressing chronic diseases and improving longevity/ lifespan.

What are the applications of the PCT patent?

With this invention, Genomic Vision technology can not only be used to detect the physical telomere lengths of DNA but can also identify regions within the genome close to telomere or elsewhere to co-relate diseases or biomarkers where telomere shortening, or loss identification is crucial.

With the use of Artificial Intelligence (AI) based module, PCT applications will lead to automatic detection and archive data for development of internal data bank.

Based on the PCT patent, the global strategy of Genomic Vision is to provide end to end bio-analytical tools for:

  • Age-related diseases;
  • Lifestyle based solutions;
  • Genome-wide telomere lengths profiling;
  • Biomarker for specific chromosome linked diseases;
  • Early prognosis of diseases;.

In Q3 2021, Genomic Vision already launched its TeloSizer® service, an innovative tool that physically measures telomere size and distribution to uncover the link between telomere length and disease onset and severity. The new patent brings essential additional new insights for determining how telomere length can serve among other things, as a potential biomarker in medicine.

Dominique Remy-Renou, CEO of Genomic Vision, stated: “We are proud to have obtained this patent, which allows us to further protect our technology in various domains of application. The intellectual property policy is an integral part of our development strategy and I would like to thank our IP team for this achievement.”

***

ABOUT GENOMIC VISION

GENOMIC VISION is a biotechnology company developing products and services dedicated to the analysis (structural and functional) of genome modifications as well as to the quality and safety control of these modifications, in particular in genome editing technologies and biomanufacturing processes. Genomic Vision proprietary tools, based on DNA combing technology and artificial intelligence, provide robust quantitative measurements needed to high confidence characterization of DNA alteration in the genome. These tools are mainly used for monitoring DNA replication in cancerous cell, for early cancer detection and the diagnosis of genetic diseases. Genomic Vision, based near Paris in Bagneux, is a public listed company listed in compartment C of Euronext’s regulated market in Paris (Euronext: GV – ISIN: FR0011799907).

For further information, please visit www.genomicvision.com

FORWARD LOOKING STATEMENT

This press release contains implicitly or explicitly certain forward-looking statements concerning Genomic Vision and its business. Such forward-looking statements are based on assumptions that Genomic Vision considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the “Risk Factors” section of the universal registration document filed with the AMF on February 9, 2021 under reference number R.21-002, available on the web site of Genomic Vision (www.genomicvision.com) and to the development of economic conditions, financial markets and the markets in which Genomic Vision operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Genomic Vision or not currently considered material by Genomic Vision. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Genomic Vision to be materially different from such forward-looking statements.

This press release and the information contained herein do not constitute and should not be construed as an offer or an invitation to sell or subscribe, or the solicitation of any order or invitation to purchase or subscribe for Genomic Vision shares in any country. The distribution of this press release in certain countries may be a breach of applicable laws. The persons in possession of this press release must inquire about any local restrictions and comply with these restrictions.

Genomic Vision Dominique Remy-Renou CEO Tel.: +33 1 49 08 07 51 investisseurs@genomicvision.com Ulysse Communication Press Relations Bruno Arabian Tel.: +33 1 42 68 29 70 barabian@ulysse-communication.com NewCap Investor Relations & Strategic Communications Tel.: +33 1 44 71 94 94 gv@newcap.eu

Goldfield (AMEX:GV)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025 Click aqui para mais gráficos Goldfield.
Goldfield (AMEX:GV)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025 Click aqui para mais gráficos Goldfield.